Reporting from ESMO Congress 2023 in Madrid, Shannon Westin discusses the results from three important studies on immunotherapy novelties in the management of patients with endometrial cancer.
- LBA40 - Phase III double-blind randomized placebo controlled trial of atezolizumab in combination with carboplatin and paclitaxel in women with advanced/recurrent endometrial carcinoma., presented by N. Colombo
- LBA41 - Durvalumab (durva) plus carboplatin/paclitaxel (CP) followed by maintenance (mtx) durva ± olaparib (ola) as a first line (1L) treatment for newly diagnosed advanced or recurrent endometrial cancer (EC): results from the Phase III DUO-E/GOG-3041/ENGOT-EN10 trial, presented by S.N. Westin
- LBA43 - Updated Response Data and Analysis of Progression Free Survival by Mechanism of Mismatch Repair Loss in Endometrial Cancer (EC) patients (pts) treated with pembrolizumab plus carboplatin/paclitaxel (CP) as compared to CP plus placebo (PBO) in the NRG GY018 trial, presented by R.N. Eskander